Evidence map›Paper›PMID 37123132›Full record

ArticleArchives of Razi Institute2022

Pharmaceutical Characterization and

H F Al-Saedi, M R Al-Notazy, M A Ramadhan, W Khaled Younis Albahadly

Open access · greenAbstract read
In one paragraph

Article in Archives of Razi Institute, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

H F Al-SaediUniversity of Al-Ameed, College of Pharmacy, Department of Pharmacology, Karbala, Iraq.
M R Al-NotazyAl-Manara University College, Department of Pharmacology, Misan, Iraq.
M A RamadhanUniversity of Misan, College of Medicine, Department of Pathology, Misan, Iraq.
W Khaled Younis AlbahadlyUniversity of Al-Ameed, College of Pharmacy, Department of Pharmacology, Karbala, Iraq.
University of Kerbala · IQUniversity of Misan · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dermatitis, like inflammation, is a group of common dermatological symptoms and may be associated with systemic and skin diseases. The objective of the current study is to evaluate the potential anti-inflammatory effect of the topical allopurinol against inflammation like skin dermatitis induced by1-isobutyl-1H-imidazo [4,5-c]quinolin-4-amine (IQA) in mice model. The current study allocated the thirty-two mice into four groups (n=8) as follows: i) control group, mice where a white petroleum jelly base applied topically on the dorsal of mice once daily; ii) induction group, mice were received IQA cream (62.5 mg) of (5%) on their back once daily; and iii) the treatment group, mice were treated with both (62.5 mg) of (5%) IQA and (5%) allopurinol gel topically; the betamethasone group, mice were treated with both (62.5 mg) of (5%) IQA and betamethasone ointment topically. All groups were treated daily for seven days period. The allopurinol-treated group exerted non-significant differences compared with the induction group in both visional and histopathological changes. The present study revealed that the allopurinolgel (5%) did not affect skin inflammation- induced by IQA in the laboratory mice.

Indexed as

AllopurinolDermatitisAnimalsAnti-Inflammatory AgentsBetamethasoneDisease Models, AnimalInflammationMiceAllopurinolAnti-Inflammatory AgentsBetamethasoneAllopurinolDermatitisInflammationIQA

Identifiers

PMID37123132
PMCPMC10133589
OpenAlexW4367601096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.